MedTrace Logo

European Trial of Free Light Chain Removal by Extended Haemodialysis in Cast Nephropathy

NCT00700531 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2016-10-05

No results posted yet for this study

Summary

Hypothesis: Free light chain removal haemodialysis will increase the rate of renal recovery in patients with cast nephropathy, severe renal failure and de novo multiple myeloma.

This study will randomise patients with multiple myeloma and severe renal failure to treatment to remove free light chains by haemodialysis or not.

Conditions

Interventions

DEVICE

FLC removal HD (Gambro HCO 1100)

FLC removal HD using a extended dialysis schedule on the Gambro HCO 1100

PROCEDURE

Standard dialysis on a high flux ployflux dialyser

Standard dialysis on a high flux ployflux dialyser at a frequency determined by the duty nephrologist

Sponsors & Collaborators

  • Gambro Renal Products, Inc.

    collaborator INDUSTRY

  • Ortho Biotech, Inc.

    collaborator INDUSTRY

  • University Hospital Birmingham

    lead OTHER

Principal Investigators

  • Paul Cockwell, PhD FRCP · University Hospital Birmingham

  • Mark Cook, PhD FRCPath · University Hospital Birmingham

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2014-01-31
Completion
2015-10-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00700531 on ClinicalTrials.gov